Berlin (Germany) and Germantown, MD (U.S.A.), November 2, 2015 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that it will host a corporate workshop at the Association for Molecular Pathology (AMP) 2015 Annual Meeting. Attendees of AMP, analysts, investors and media representatives are cordially invited to join this event on November 4, 2015, at 4pm CDT in room 17A at the Austin Convention Center, Austin, TX.
The workshop will provide an update on Epigenomics’ colorectal and lung cancer programs. First, the Company will present trials demonstrating patient willingness to accept Septin9 plasma screening for colorectal cancer. Subsequently, an update on the deployment of the Septin9 test into the clinical laboratory setting will be provided. Finally, data on the performance of the company’s liquid biopsy marker panel using Real-Time PCR methylation detection for lung cancer detection will be presented. Following the workshop, there will be an opportunity for discussion of the studies and applications for epigenetic biomarkers in oncology with Epigenomics’ technology group.
The workshop will be hosted by Dr. Thomas Taapken, CEO/CFO of Epigenomics AG, and Noel Doheny, CEO of Epigenomics’ US subsidiary. Presentations will be held by:
• Theo deVos PhD, Director, Development & Commercial Operations, North America Epigenomics, Inc.,
“Will the Availability of a Blood Test Increase CRC Screening Participation in the Non-Adherent Population?”
• Nicholas Potter, PhD, FACMG, Executive Vice President, Clinical Affairs, Molecular Pathology Laboratory Network, Inc. Maryville, TN
“Cancer Screening: Bringing Blood-based Epigenetic Cancer Testing into the Clinical Laboratory”
• Uwe Staub PhD, Chief Operating Officer, Epigenomics AG, Berlin, Germany
“An Emerging Tool for Lung Cancer Management”
“We are highly committed to drive innovation in the field of blood-based cancer detection using our epigenetic tests,” said Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “In this respect, AMP 2015 represents an important opportunity to share new data from our colorectal and lung cancer programs with the medical and laboratory community.”
About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon(R), is a blood-based screening test for the early detection of colorectal cancer and is currently marketed in Europe and China. For more information, visit www.epigenomics.com.
Contact Epigenomics AG
Peter Vogt
Investor & Public Relations
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com
Help employers find you! Check out all the jobs and post your resume.
